A technique for turning genes off has sparked a flurry of biotech investment. Erika Check investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zamore, P. D., Tuschl, T., Sharp, P. A. & Bartel, D. P. Cell 101, 25–33 (2000).
Elbashir, S. M. et al. Nature 411, 494–498 (2001).
Zimmermann, T. S. et al. Nature 441, 111–114 (2006).
Related links
Related links
Related links in Nature Research
Safety concerns raised over RNA interference
RNA therapy tackles eye disease
Firm sets sights on gene silencing to protect vision
RNA therapy beckons as firms prepare for clinical trials
Gene regulation: RNA to the rescue?
Patent flurry casts cloud over gene silencing
Related external links
Rights and permissions
About this article
Cite this article
Silent running: the race to the clinic. Nature 442, 614–615 (2006). https://doi.org/10.1038/442614a
Published:
Issue Date:
DOI: https://doi.org/10.1038/442614a
This article is cited by
-
Hitting the on switch
Nature (2007)